179 related articles for article (PubMed ID: 35137546)
1. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
[TBL] [Abstract][Full Text] [Related]
2. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
[TBL] [Abstract][Full Text] [Related]
5. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.
Mora J; Gerald WL; Qin J; Cheung NK
Cancer; 2002 May; 94(10):2756-65. PubMed ID: 12173347
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
[TBL] [Abstract][Full Text] [Related]
7.
Yue ZX; Huang C; Gao C; Xing TY; Liu SG; Li XJ; Zhao Q; Wang XS; Zhao W; Jin M; Ma XL
Cancer Cell Int; 2017; 17():43. PubMed ID: 28367105
[No Abstract] [Full Text] [Related]
8. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
9. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.
García-López J; Wallace K; Otero JH; Olsen R; Wang YD; Finkelstein D; Gudenas BL; Rehg JE; Northcott P; Davidoff AM; Freeman KW
Cell Rep; 2020 Jan; 30(2):454-464.e5. PubMed ID: 31940489
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
11. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
13. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
Scaruffi P; Parodi S; Mazzocco K; Defferrari R; Fontana V; Bonassi S; Tonini GP
Mol Diagn; 2004; 8(2):93-100. PubMed ID: 15527323
[TBL] [Abstract][Full Text] [Related]
14. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
15. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.
Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ
Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
Maris JM; Guo C; Blake D; White PS; Hogarty MD; Thompson PM; Rajalingam V; Gerbing R; Stram DO; Matthay KK; Seeger RC; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):32-6. PubMed ID: 11464900
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
19. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bioinformatic analysis.
Wang H; Wang X; Xu L
Ital J Pediatr; 2023 Oct; 49(1):145. PubMed ID: 37904225
[TBL] [Abstract][Full Text] [Related]
20. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
